Physician profile
Matthew Gray
NPI 1477789543
$6,003.00
in general payments reported to CMS, 2019-2025
33 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $840 · 2021: $1,377 · 2022: $777 · 2023: $386 · 2024: $562 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853 · Travel and Lodging: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,852.64 |
| Travel and Lodging | $151.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,477.50 | 2019-2025 | Centurion, Rocklatan, Hydrus Microstent |
| New World Medical,INC. | $754.46 | 2019-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Kala Pharmaceuticals, INC. | $501.55 | 2020-2022 | |
| Sight Sciences, INC. | $380.78 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Sun Pharmaceutical Industries INC. | $340.16 | 2019-2022 | |
| Oyster Point Pharma, INC. | $261.79 | 2022-2024 | Tyrvaya |
| Biohaven Pharmaceuticals, INC. | $250.56 | 2021 | |
| Bausch & Lomb Americas INC. | $229.13 | 2022-2025 | Envista Mx60 Iol |
| Biotissue Holdings INC. | $163.00 | 2019-2021 | |
| Abbott Laboratories | $151.03 | 2025 | Proclaim |
| Johnson & Johnson Surgical Vision, INC. | $147.11 | 2019-2023 | Tecnis Iol |
| Abbvie INC. | $140.87 | 2022-2025 | |
| Viiv Healthcare Company | $117.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $111.24 | 2019-2023 | |
| Harrow Eye, LLC | $107.41 | 2024-2025 | Iheezo, Vevye |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $102.44 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $100.55 | 2024-2025 | Xdemvy |
| Spark Therapeutics, INC. | $85.82 | 2019 | |
| Novo Nordisk INC | $85.79 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $65.88 | 2019-2021 | |
| Amgen INC. | $63.50 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $62.76 | 2022-2025 | Acthar |
| Glaukos Corporation | $49.31 | 2021-2025 | Idosetr |
| Rayner Intraocular Lenses Limited | $41.48 | 2023-2024 | Rayone Aspheric, Omidria, Rayone Emv |
| Thea Pharma INC. | $39.53 | 2023-2024 | Iyuzeh |
| Rxsight INC | $39.52 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Allergan, INC. | $32.28 | 2021 | |
| Boston Scientific Corporation | $23.32 | 2022 | |
| Dompe US, INC. | $20.17 | 2021 | |
| Eyepoint US, INC. | $19.02 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $12.95 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.70 | 2019 | |
| Genentech USA, INC. | $12.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.